Covid Vaccine Race

January 29th 2025

James F Cummings, MD discusses phase 2b trial Phase 2b trial expansion focusing on safety, efficacy, and immune response for Vaxart’s investigational oral vaccine.

October 16th 2024

A serious adverse event of motor neuropathy reported in September 2024 has resulted in a hold on the investigational new drug application.

September 10th 2024

Recent data and conversations with experts highlighted the increasing concern of Long COVID’s impact on the brain in patients who have been previously infected with the virus.

August 30th 2024

Approved for individuals aged 12 years and older, this vaccine features a monovalent component and replaces the previous Novavax formula.